The ARG tyrosine kinase is inhibited by STI571.

被引：0
|
作者：
Okuda, K
Weisberg, E
Gilliland, DG
Griffin, JD
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1487
引用
收藏
页码：344A / 344A
页数：1
相关论文
共 50 条
  • [41] ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase
    Xiong, Yuan-Zhen
    Chen, Pei-Yu
    JOURNAL OF MOLECULAR MODELING, 2008, 14 (11) : 1083 - 1086
  • [42] The tyrosine kinase inhibitor STI571 prolongs survival in a murine model of chronic myelogenous leukemia.
    Wolff, NC
    Xu, HM
    Zhang, SM
    Ilaria, RL
    BLOOD, 2000, 96 (11) : 344A - 344A
  • [43] Cell cycle arrest does not protect K562 cells from proapoptotic effects of STI571.
    La Rosée, P
    O'Dwyer, M
    Bakke, A
    Shen, L
    Druker, BJ
    BLOOD, 2001, 98 (11) : 616A - 617A
  • [44] The chromosomal complexity score (CCS) as a predictive factor for response of patients with CML in accelerated phase to treatment with STI571.
    Marin, D
    Bua, M
    Marktel, S
    Chase, A
    Armstrong, L
    Udom, C
    Olavarria, E
    Apperley, JF
    Goldman, JM
    BLOOD, 2001, 98 (11) : 262B - 262B
  • [45] Chronic Myeloproliferative diseases with t(5;12) and a PDGFRB fusion gene:: Complete cytogenetic remissions on STI571.
    Apperley, JF
    Schultheis, B
    Chase, A
    Steer, J
    Bain, B
    Dimitríjevic, S
    Marin, D
    Olavarria, E
    Cross, N
    Russell-Jones, R
    Melo, J
    Goldman, J
    BLOOD, 2001, 98 (11) : 726A - 726A
  • [46] Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
    Wang, WL
    Healy, ME
    Sattler, M
    Verma, S
    Lin, J
    Maulik, G
    Stiles, CD
    Griffin, JD
    Johnson, BE
    Salgia, R
    ONCOGENE, 2000, 19 (31) : 3521 - 3528
  • [47] Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
    Wen-Lan Wang
    Mary Ellen Healy
    Martin Sattler
    Shalini Verma
    Jeffrey Lin
    Gautam Maulik
    Charles D Stiles
    James D Griffin
    Bruce E Johnson
    Ravi Salgia
    Oncogene, 2000, 19 : 3521 - 3528
  • [48] The size of high molecular weight complexes of ABL formed by different oligomerization interfaces may influence the sensitivity to STI571.
    Beissert, T
    Bianchini, A
    Hoelzer, D
    Ottmann, OG
    Nervi, C
    Ruthardt, M
    BLOOD, 2002, 100 (11) : 584A - 585A
  • [49] Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571
    Prejzner, W
    Knopinska-Posluszny, W
    Mikolajczuk, J
    Langowska, B
    Hellmann, A
    CLINICAL AND LABORATORY HAEMATOLOGY, 2003, 25 (05): : 293 - 296
  • [50] Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells
    Majsterek, Ireneusz
    Arabski, Michal
    Czechowska, Agnieszka
    Pytel, Dariusz
    Morawiec, Zbigniew
    Morawiec-Bajda, Alina
    Blasiak, Janusz
    ZEITSCHRIFT FUR NATURFORSCHUNG SECTION C-A JOURNAL OF BIOSCIENCES, 2006, 61 (11-12): : 896 - 902
12345